Tivozanib intermediates

 

Fotivda (tivozanib)

CAS RN: 475108-18-0

Chemical Name:

1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea

Company: AVEO Pharmaceuticals

 

Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Tivozanib is a Kinase Inhibitor. The mechanism of action is as a Tyrosine Kinase Inhibitor

One synthetic route

 

Tivozanib intermediates

3',4'-Dimethoxyacetophenone 1131-62-0

4',5'-Dimethoxy-2'-nitroacetophenone 4101-32-0

4-Hydroxy-6,7-dimethoxyqunioline 13425-93-9

4-Chloro-6,7-dimethoxyquioline 35654-56-9

4-Amino-3-chlorophenol hydrochloride 52671-64-4

4-Amino-3-chlorophenol 17609-80-2

3-Amino-5-methylisoxazole 1072-67-9

Phenyl chloroformate 1885-14-9